Next Article in Journal
Examples of Weak, If Not Absent, Form-Function Relations in the Vertebrate Heart
Previous Article in Journal
The Anatomy, Development, and Evolution of the Atrioventricular Conduction Axis
Article Menu

Export Article

Open AccessReview
J. Cardiovasc. Dev. Dis. 2018, 5(3), 45; https://doi.org/10.3390/jcdd5030045

TREM-1; Is It a Pivotal Target for Cardiovascular Diseases?

Department of Clinical and Translational Sciences, School of Medicine, Creighton University, Omaha, NE 68178, USA
Both authors contributed equally.
*
Author to whom correspondence should be addressed.
Received: 20 August 2018 / Revised: 2 September 2018 / Accepted: 4 September 2018 / Published: 7 September 2018
Full-Text   |   PDF [2053 KB, uploaded 7 September 2018]   |  

Abstract

Cardiovascular diseases (CVDs) are as menacing as ever and still continue to kill adults worldwide, notwithstanding tremendous efforts to decrease their consequent mortality and morbidity. Lately, a growing body of research indicated that inflammation plays a pivotal role in the pathogenesis and complications of CVDs. A receptor of the immunoglobulin superfamily, triggering receptors expressed on myeloid cells-1 (TREM-1) was shown to induce and amplify the inflammation in both acute and chronic disease’ pathogenesis and progression, which hence makes it one of the most important complication factors of CVDs. Thus, studies endeavored to investigate the role played by TREM-1 in CVDs with respect to their etiologies, complications, and possible therapeutics. We examined here, for the first time, the most relevant studies regarding TREM-1 involvement in CVDs. We critically analyzed and summarized our findings and made some suggestions for furtherance of the investigations with the aim to utilize TREM-1 and its pathways for diagnostic, management, and prognosis of CVDs. Overall, TREM-1 was found to be involved in the pathogenesis of acute and chronic cardiovascular conditions, such as acute myocardial infarction (AMI) and atherosclerosis. Although most therapeutic approaches are yet to be elucidated, our present research outcome displays a promising future to utilizing the TREM-1 pathway as a potential target for understanding and managing CVDs. View Full-Text
Keywords: triggering receptor expressed on myeloid cells; DNAX-activating protein 12; cardiovascular diseases; atherosclerosis; coronary arteries diseases; acute myocardial infract; endocarditis triggering receptor expressed on myeloid cells; DNAX-activating protein 12; cardiovascular diseases; atherosclerosis; coronary arteries diseases; acute myocardial infract; endocarditis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kouassi, K.T.; Gunasekar, P.; Agrawal, D.K.; Jadhav, G.P. TREM-1; Is It a Pivotal Target for Cardiovascular Diseases? J. Cardiovasc. Dev. Dis. 2018, 5, 45.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Cardiovasc. Dev. Dis. EISSN 2308-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top